Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Yale University
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06058702CT.gov Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans | — | Recruiting | — | — | — |
NCT04605393CT.gov Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cannabis Dependence
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Delta-9-Thc (this asset) | Yale University | P1 | CC · 43 |
| Clozapine | Dartmouth-Hitchcock Medical Center | P4 | BB |
| Topiramate | University of Cincinnati | P4 | BB |
| Risperidone | Dartmouth-Hitchcock Medical Center | P4 | BB |
| Metformin | Nova Scotia Health Authority | P4 | BB |
| Quetiapine | University of Cincinnati | P4 | B |
| Tirzepatide | McMaster University | P3 | B |
| Clonidine | Mclean Hospital | P2/3 | B |
| Fluoxetine | University of Pittsburgh | P2 | B |
+5 more in the Cannabis Dependence cohort
Other indications for Delta-9-Thc
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bipolar Disorder | — | P1 | C · 39 |
| Schizophrenia | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Delta-9-Thc in Cannabis Dependence. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/delta-9-thc-cannabis-dependence-108496
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →